EntreMed, Inc. To Present At SG Cowen & Co., LLC 26th Annual Health Care Conference

ROCKVILLE, Md., Feb. 28 /PRNewswire-FirstCall/ -- EntreMed, Inc. a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that James S. Burns, President and Chief Executive Officer, will present a Corporate overview at the SG Cowen 26th Annual Health Care Conference, to be held at the Boston Marriott Copley Place, March 6-9, 2006. Mr. Burns' presentation is scheduled for Tuesday, March 7, 2006 at 4:00 p.m. (local time).

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Mr. Burns' live presentation will be web cast and can be accessed through the Company's web site at www.entremed.com. An archive will be available on the web site for approximately 90 days.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. Panzem (2-methoxyestradiol or 2ME2), the Company's lead drug candidate, is currently in Phase 2 clinical trials for cancer, as well as in preclinical development for rheumatoid arthritis. MKC-1, recently acquired through the Company's acquisition of Miikana Therapeutics, is also in Phase 2 studies for cancer. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's website at www.entremed.com and in various filings with the Securities and Exchange Commission.

Ginny Dunn Associate Director Corporate Communications Investor Relations EntreMed, Inc. 240-864-2643

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comEntreMed, Inc.

CONTACT: Ginny Dunn, Associate Director Corporate Communications, InvestorRelations, EntreMed, Inc., +1-240-864-2643

Back to news